Survival outcome is similar for first-line chemotherapy with capecitabine or taxane for metastatic breast cancer

被引：0
|
作者：
Kimmick, G. G.
Camacho, F.
Wei, W.
Balkrishnan, R.
Anderson, R.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Penn State Coll Med, Hershey, PA USA
[3] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
[4] Ohio State Univ, Sch Publ Hlth, Columbus, OH 43210 USA
[5] Roche, Nutley, NJ USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：374S / 374S
页数：1
相关论文
共 50 条
  • [41] First-line all-oral NORCAP (vinorelbine/capecitabine) might be alternative to taxane-based chemotherapy for HER2-negative metastatic breast cancer
    Kadri Altundag
    Breast Cancer Research and Treatment, 2017, 161 : 385 - 385
  • [42] Capecitabine and weekly paclitaxel as first-line therapy in Thai patients with metastatic breast cancer
    Chitapanarux, Imjai
    Kamnerdsupaphon, Pimkhuan
    Tharavichitkul, Ekasit
    Lorvidhaya, Vicharn
    Trakultivakorn, Hongsin
    Srisukho, Songpol
    Somwangprasert, Areewan
    Watcharachan, Kirati
    Sukthomya, Vimol
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2012, 8 (01) : 76 - 82
  • [43] NICE guidance on bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer
    Umeweni, Nwamaka
    Nolan, Kay
    Knight, Helen
    Clark, Peter
    LANCET ONCOLOGY, 2012, 13 (10): : 977 - 978
  • [44] Oral vinorelbine and capecitabine as first-line therapy in metastatic breast cancer: a retrospective analysis
    Valerio, Maria Rosaria
    Spadaro, Pietro
    Arcana, Concetta
    Borsellino, Nicolo
    Cipolla, Calogero
    Vigneri, Paolo
    Piazza, Dario
    Gebbia, Vittorio
    FUTURE SCIENCE OA, 2021, 7 (10):
  • [45] Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
    Hans-Joachim Lück
    Kristina Lübbe
    Mattea Reinisch
    Nicolai Maass
    Gabriele Feisel-Schwickardi
    Oliver Tomé
    Wolfgang Janni
    Mustafa Aydogdu
    Tanja Neunhöffer
    Angelika Ober
    Bahriye Aktas
    Tjoung-Won Park-Simon
    Claudia Schumacher
    Heinz-Gert Höffkes
    Thomas Illmer
    Harald Wagner
    Keyur Mehta
    Gunter von Minckwitz
    Valentina Nekljudova
    Sibylle Loibl
    Breast Cancer Research and Treatment, 2015, 149 : 141 - 149
  • [46] Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer
    Lueck, Hans-Joachim
    Luebbe, Kristina
    Reinisch, Mattea
    Maass, Nicolai
    Feisel-Schwickardi, Gabriele
    Tome, Oliver
    Janni, Wolfgang
    Aydogdu, Mustafa
    Neunhoeffer, Tanja
    Ober, Angelika
    Aktas, Bahriye
    Park-Simon, Tjoung-Won
    Schumacher, Claudia
    Hoeffkes, Heinz-Gert
    Illmer, Thomas
    Wagner, Harald
    Mehta, Keyur
    von Minckwitz, Gunter
    Nekljudova, Valentina
    Loibl, Sibylle
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 149 (01) : 141 - 149
  • [47] Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer
    Vrdoljak, E.
    Boban, M.
    Omrcen, T.
    Hrepic, D.
    Fridl-Vidas, V.
    Boskovic, L.
    NEOPLASMA, 2011, 58 (02) : 172 - 178
  • [48] Efficacy of Bevacizumab-Capecitabine in Combination for the First-Line Treatment of Metastatic Breast Cancer
    Dyar, Stephen
    Moreno-Aspitia, Alvaro
    BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2011, 5 : 239 - 246
  • [49] Results of a phase I trial of intravenous vinorelbine plus oral capecitabine as first-line chemotherapy of metastatic breast cancer
    Favier, Laure
    Isambert, Nicolas
    Zanetta, Sylvie
    Ferrant, Ernmanuelle
    Mayer, Francoise
    Chauffert, Bruno
    Fumoleau, Pierre
    Garnier, Jerome
    Biville, Fabienne
    Coudert, Bruno
    BREAST, 2008, 17 (01): : 36 - 41
  • [50] Review of gemcitabine plus taxane combination therapy in the first-line treatment of metastatic breast cancer
    Colomer, Ramon
    EJC SUPPLEMENTS, 2008, 6 (04): : 9 - 12
12345